The Epidemiology of Neuroendocrine Tumors in Taiwan: a Nation-wide Cancer Registry-based Study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Apr 25

PMID 23614051

Citations 79

Authors

Hui-Jen Tsai

Chun-Chieh Wu

Chia-Rung Tsai

Sheng-Fung Lin

Li-Tzong Chen

Jeffrey S Chang

Affiliations

Soon will be listed here.

Abstract

Background: The epidemiology of neuroendocrine tumors (NETs) is not well illustrated, particularly for Asian countries.

Methods: The age-standardized incidence rates and observed survival rates of NETs diagnosed in Taiwan from January 1, 1996 to December 31, 2008 were calculated using data of the Taiwan Cancer Registry (TCR) and compared to those of the Norwegian Registry of Cancer (NRC) and the US Surveillance, Epidemiology, and End Results (SEER) program.

Results: During the study period, a total of 2,187 NET cases were diagnosed in Taiwan, with 62% males and a mean age of 57.9 years-old. The age-standardized incidence rate of NETs increased from 0.30 per 100,000 in 1996 to 1.51 per 100,000 in 2008. The most common primary sites were rectum (25.4%), lung and bronchus (20%) and stomach (7.4%). The 5-year observed survival was 50.4% for all NETs (43.4% for men and 61.8% for women, P<0.0001). The best 5-year observed survivals for NETs by sites were rectum (80.9%), appendix (75.7%), and breast (64.8%).

Conclusions: Compared to the data of Norway and the US, the age-standardized incidence rate of NETs in Taiwan is lower and the major primary sites are different, whereas the long-term outcome is similar. More studies on the pathogenesis of NETs are warranted to devise preventive strategies and improve treatment outcomes for NETs.

Citing Articles

Outcome of Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Progressive Metastatic Neuroendocrine Tumors from a Tertiary Care Center.

Mathew D, Sunny S, Benjamin J, John J, Jebasingh F, Georgy J Indian J Endocrinol Metab. 2025; 28(6):601-610.

PMID: 39881767 PMC: 11774412. DOI: 10.4103/ijem.ijem_372_23.

Impact of sex differences on patients with neuroendocrine neoplasms during hospital admission.

Tan W, Cramer L, Vijayvergia N, Lustberg M, Kunz P Ther Adv Med Oncol. 2024; 16:17588359241292271.

PMID: 39687054 PMC: 11648047. DOI: 10.1177/17588359241292271.

Time trend analysis of rare cancer incidence 2011-2018: Nationwide population-based cancer registries in Japan.

Sugiyama H, Konda M, Saika K, Matsuda T Cancer Sci. 2024; 115(7):2417-2443.

PMID: 38613332 PMC: 11247610. DOI: 10.1111/cas.16176.

Gastric neuroendocrine neoplasms.

Lamberti G, Panzuto F, Pavel M, OToole D, Ambrosini V, Falconi M Nat Rev Dis Primers. 2024; 10(1):25.

PMID: 38605021 DOI: 10.1038/s41572-024-00508-y.

Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors.

Kim J, Kim J, Kim Y, Yang D, Yoo C, Park I Sci Rep. 2024; 14(1):4047.

PMID: 38374188 PMC: 10876978. DOI: 10.1038/s41598-024-54599-4.

References

Shin H . [Global activity of cancer registries and cancer control and cancer incidence statistics in Korea]. J Prev Med Public Health. 2008; 41(2):84-91. View

Lepage C, Bouvier A, Phelip J, Hatem C, Vernet C, Faivre J . Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut. 2004; 53(4):549-53. PMC: 1774002. DOI: 10.1136/gut.2003.026401. View

Yao J, Shah M, Ito T, Bohas C, Wolin E, Van Cutsem E . Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):514-23. PMC: 4208619. DOI: 10.1056/NEJMoa1009290. View

Naranjo Gomez J, Gomez Roman J . Behaviour and survival of high-grade neuroendocrine carcinomas of the lung. Respir Med. 2010; 104(12):1929-36. DOI: 10.1016/j.rmed.2010.08.007. View

Hassan M, Phan A, Li D, Dagohoy C, Leary C, Yao J . Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study. Int J Cancer. 2008; 123(4):867-73. DOI: 10.1002/ijc.23529. View

Lee H, Lee E, Ha S, Lee C, Chang H, Chang S . Altered expression of microRNA miR-21, miR-155, and let-7a and their roles in pulmonary neuroendocrine tumors. Pathol Int. 2012; 62(9):583-91. DOI: 10.1111/j.1440-1827.2012.02845.x. View

Tsuta K, Liu D, Kalhor N, Wistuba I, Moran C . Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas. Am J Clin Pathol. 2011; 136(2):252-9. DOI: 10.1309/AJCPDXFOPXGEF0RP. View

Yao J, Phan A, Chang D, Wolff R, Hess K, Gupta S . Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008; 26(26):4311-8. PMC: 2653122. DOI: 10.1200/JCO.2008.16.7858. View

Larsen I, Smastuen M, Johannesen T, Langmark F, Parkin D, Bray F . Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2008; 45(7):1218-1231. DOI: 10.1016/j.ejca.2008.10.037. View

10.

Caldarella A, Crocetti E, Paci E . Distribution, incidence, and prognosis in neuroendocrine tumors: a population based study from a cancer registry. Pathol Oncol Res. 2011; 17(3):759-63. DOI: 10.1007/s12253-011-9382-y. View

11.

Aydin E, Yazici U, Gulgosteren M, Agackiran Y, Kaya S, Gulhan E . Long-term outcomes and prognostic factors of patients with surgically treated pulmonary carcinoid: our institutional experience with 104 patients. Eur J Cardiothorac Surg. 2011; 39(4):549-54. DOI: 10.1016/j.ejcts.2010.08.010. View

12.

Niederle M, Hackl M, Kaserer K, Niederle B . Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010; 17(4):909-18. DOI: 10.1677/ERC-10-0152. View

13.

Bray F, Parkin D . Evaluation of data quality in the cancer registry: principles and methods. Part I: comparability, validity and timeliness. Eur J Cancer. 2009; 45(5):747-55. DOI: 10.1016/j.ejca.2008.11.032. View

14.

Hemminki K, Li X . Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer. 2001; 92(8):2204-10. DOI: 10.1002/1097-0142(20011015)92:8<2204::aid-cncr1564>3.0.co;2-r. View

15.

Raymond E, Dahan L, Raoul J, Bang Y, Borbath I, Lombard-Bohas C . Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):501-13. DOI: 10.1056/NEJMoa1003825. View

16.

Yao J, Hassan M, Phan A, Dagohoy C, Leary C, Mares J . One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18):3063-72. DOI: 10.1200/JCO.2007.15.4377. View

17.

Ali G, Boldrini L, Capodanno A, Pelliccioni S, Servadio A, Crisman G . Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumors. Exp Ther Med. 2012; 2(5):787-792. PMC: 3440723. DOI: 10.3892/etm.2011.291. View

18.

Johnson R, Trocha S, McLawhorn M, Worley M, Wheeler G, Thompson L . Histology, not lymph node involvement, predicts long-term survival in bronchopulmonary carcinoids. Am Surg. 2012; 77(12):1669-74. View

19.

Wiedenmann B, Pavel M, Kos-Kudla B . From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors. Neuroendocrinology. 2011; 94(3):177-90. DOI: 10.1159/000329386. View

20.

Ito T, Sasano H, Tanaka M, Yoshiyuki Osamura R, Sasaki I, Kimura W . Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol. 2010; 45(2):234-43. DOI: 10.1007/s00535-009-0194-8. View